The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Carlos F. Barbas sits on this spectrum.
This scientist: 470 publications — 94th percentile
94% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 1,028 publications or more.
The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Carlos F. Barbas sits on this spectrum.
This scientist: 130 D-Index — 98th percentile
98% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 167 D-Index or more.
Carlos F. Barbas was affiliated with the Scripps Research Institute in the United States. Their research contributions primarily spanned the fields of biochemistry, genetics, and molecular biology, with a focus on several specialized subfields including molecular biology, radiology, nuclear medicine and imaging, biomaterials, and virology.
Their published work included topics related to monoclonal and polyclonal antibodies research, glycosylation and glycoproteins research, nanoparticle-based drug delivery, CRISPR and genetic engineering, RNA interference and gene delivery, as well as HIV research and treatment.
The scientist regularly collaborated with several co-authors over their career. Frequent collaborators included:
Barbas's publications appeared in notable scientific venues such as Pharmaceutics and Molecular Therapy - Methods & Clinical Development. Their research outputs in these journals reflected intersections between molecular biology techniques and therapeutic delivery systems, particularly focusing on antibody engineering and HIV treatment strategies.
Their work in nanoparticle-based drug delivery and gene delivery mechanisms contributed to the understanding of targeted therapeutic approaches. This included innovative methods for crossing biological barriers and stimulating viral activation in latent infections.
Throughout their career, the scientist focused on advancing molecular biology applications related to genetic engineering and immune system modulation. Their interdisciplinary collaborations and contributions across multiple fields helped characterize complex biological systems, integrating molecular insights with clinical development themes.
Thomas Gaj;Charles A. Gersbach;Carlos F. Barbas
Benjamin List;Richard A. Lerner;Carlos F. Barbas
Carlos F. Barbas;Angray S. Kang;Richard A. Lerner;Stephen J. Benkovic
Kandasamy Sakthivel;Wolfgang Notz;Tommy Bui;Carlos F. Barbas
Lin Jiang;Eric A. Althoff;Fernando R. Clemente;Lindsey Doyle
Dennis R. Burton;Jayashree Pyati;Raju Koduri;Stephen J. Sharp
Carlos F. Barbas
Thomas Holbro;Roger R. Beerli;Francisca Maurer;Magdalena Koziczak
Angray Kang;Carlos F. Barbas;Richard A. Lerner
Dennis R. Burton;Carlos F. Barbas;Mats A. A. Persson;Scott Koenig
Roger R. Beerli;David J. Segal;Birgit Dreier;Carlos F. Barbas
Angray S. Kang;Carlos F. Barbas;Kim D. Janda;Stephen J. Benkovic
Roger R. Beerli;Carlos F. Barbas
Carlos F. Barbas;J. D. Bain;Denise M. Hoekstra;Richard A. Lerner
A Trkola;A B Pomales;H Yuan;B Korber
J. P. Moore;Yunzhen Cao;Limo Qing;Q. J. Sattentau
Wei-Ping Yang;Kimberly Green;Sally Pinz-Sweeney;Amelia T. Briones
David J. Segal;Birgit Dreier;Roger R. Beerli;Carlos F. Barbas
Hermann Gram;Lori-Anne Marconi;Carlos F. Barbas Iii;Thomas A. Collet
Jürgen Wagner;Richard A. Lerner;Carlos F. Barbas
If you think any of the details on this page are incorrect, let us know.
